ASDs
The Evolving Science of Amorphous Solid Dispersions
Pharma's Almanac
PAO-10-26-PA-13Oct 20, 2026
Formulation Models
Predictive Formulation: Can Modeling Reduce Empirical Development?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-26-PA-04Oct 7, 2026
Pathfinder
Spray-Dried Dispersions vs. Nanocrystals: Which Is Better for Solubility Enhancement?
Nice Insight
PAO-26-PF-27Oct 2, 2026
Pathfinder
Micronization vs. Nanomilling vs. Amorphous Solid Dispersions: Which Is Better for Poorly Soluble Drugs?
Nice Insight
PAO-26-PF-26Sep 25, 2026
AMT Designation
AustinPx’s KinetiSol™ Technology Receives FDA Advanced Manufacturing Technology Designation
AustinPx
PR-09-26-04Sep 23, 2026
Child Formulation
The Pediatric Formulation Gap
Pharma's Almanac
PAO-09-26-PA-05Sep 7, 2026
TPDs
Low Dose, High Impact: Microdosing, Content Uniformity, and Precision Control in TPDs
David O’Connell
PCI Pharma Services
PAO-08-26-CL-04Aug 31, 2026
New Brand
QPharma Builds on a Trusted Legacy to Shape the Future of Complex Drug Delivery
QPharma
PR-08-26-04Aug 31, 2026
ADC Formulation
Controlling Complexity in ADC Formulation Development
Eunbi Iris Cho, Ph.D.
Samsung Biologics
PAO-07-26-CL-04Jul 28, 2026
Combination Products
Collaboration is Key to Successful Injectable Drug–Device Combination Product Development
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-05Jul 27, 2026
High-Concentration
High-Concentration Biologics Are Redefining Subcutaneous Delivery
Pharma's Almanac
PAO-07-26-PA-08Jul 15, 2026
LAI Formulation
The Formulation Science Behind Extended Drug Release
Pharma's Almanac
PAO-07-26-PA-03Jul 9, 2026
Drug–Device
Designing Formulations Around Devices Rather Than Vice Versa
Pharma's Almanac
PAO-07-26-PA-04Jul 7, 2026
Bioavailability
AustinPx Expands KinetiSol™ Technology Commercial Access through Thermo Fisher Scientific Collaboration
AustinPx
PR-06-26-03Jun 30, 2026
Partnership
The Solubility Company and Persist AI Unveil Strategic Partnership to Bridge the Data Gap in AI-Driven Drug Formulation
The Solubility Company
PR-05-26-02May 13, 2026
Oral mAbs
Oral Delivery of Monoclonal Antibodies: The Pursuit Continues
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-04-26-PA-05Apr 7, 2026
Neuro CMC
Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-03Apr 3, 2026
Formulation
Quotient Sciences and Intrepid Labs form Strategic Partnership to Accelerate AI-guided Formulation Development
Quotient Sciences
PR-04-26-05Apr 1, 2026
Long-Acting Delivery
Long-Acting Drug Delivery for Chronic Metabolic and Renal Conditions
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-26-PA-13Mar 23, 2026
Autoinjectors
Why Autoinjectors Fail After Phase III — and Why It’s Not a Device Problem
David Alvaro, Ph.D.
Pharma's Almanac
PAO-01-26-NI-14Jan 14, 2026